FDA Says No to Dasotraline for ADHD FDA Says No to Dasotraline for ADHD

The agency requests additional efficacy and tolerability data for the investigational dual-acting dopamine and norepinephrine reuptake inhibitor for treatment of attention-deficit/hyperactivity disorder (ADHD).Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news